Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

BENZODIAZEPINE TRANQUILIZERS AS A “GOLD STANDARD” FOR THE TREATMENT OF PATIENTS WITH ALCOHOL WITHDRAWAL SYNDROME (LITERATURE REVIEW)

V.Yu. Skryabin1, M.S. Zastrozhin1, 2, E.A. Brun1, 2, D.A. Sychev 2
1
Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare, 37/1 Lyublinskaya street, Moscow, Russia, 109390
2 Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, 2/1 Barrikadnaya street, Moscow, Russian Federation, 123995

Summary The article presents a review of modern scientific publications related to the use of benzodiazepine tranquilizers in the treatment of patients with alcohol withdrawal syndrome (AWS). More than 50 % of alcohol-consuming patients who need pharmacological treatment have the symptoms of AWS. Benzodiazepines are the medications of choice for the treatment of anxiety, fear, and emotional tension within AWS. However, therapy is often ineffective and some patients develop dose-dependent adverse drug reactions (ADRs), which reduce the treatment efficacy for this category of patients. Objective: to systematize scientific data on the use of benzodiazepines in the treatment of patients with alcohol withdrawal syndrome (AWS).
Objectives: To analyze publications on the use of benzodiazepine tranquilizers in the treatment of patients with AWS. To summarize the results of pharmacoepidemiological studies on the frequency of occurrence of ineffective cases of treatment with AWS tranquilizers, and cases of development of dose-dependent adverse drug reactions (ADR). To analyze the reasons that can influence the individual response of benzodiazepine therapy, worsening the effectiveness and safety.
Conclusions: The individual characteristics of the patient, both associated with the clinic of SOA and with the polymorphism of genes encoding elements of the pharmacokinetics and pharmacodynamics of drugs, can affect the effectiveness and safety of therapy with benzodiazepine tranquilizers. Research Material and Methods: Representative research databases PubMed and Google Scholar were used as research material. A literature search was conducted between 2010 and 2019. The following words and combinations were used as search tools: alcohol withdrawal, AWS, benzodiazepines, BDZ, diazepam, lorazepam, alcoholism, alcohol addiction, alcohol dependence, alcohol abuse, alcohol use disorder.

Citation:
V.Yu. Skryabin, M.S. Zastrozhin, E.A. Brun, D.A. Sychev. Benzodiazepine tranquilizers as a “gold standard” for the treatment of patients with alcohol withdrawal syndrome (literature review) // Sovrem. ter. psih. rasstrojstv. – 2020. – Vol. 1. – P. 24-31.– DOI: 10.21265/PSYPH.2020.33.41.003.

References

1. Koshkina E.A., Kirzhanova V.V., Vy`shinskij K.V. E`pidemiologiya alkogolizma (Narkologiya. Nacional`noe rukovodstvo) / pod red. N.N. Ivancza, I.P. Anoxinoj, M.A. Vinnikovoj. – M.: GE`OTAR-Media, 2016. – 944 s.
2. Koshkina E.A., Pavlovskaya N.I., Yagudina R.I., Kulikov A.Yu., Usenko K.Yu., Zemskova N.A. Mediko-social`ny`e i e`konomicheskie posledstviya zloupotrebleniya alkogolem v Rossii // Narkologiya. – 2009. – T. 8, № 11. – S. 29–34.
3. Global status report on alcohol and health 2018. – Geneva: World Health Organization, 2018. – Licence: CC BY-NC-SA 3.0 IGO.
4. Erdozain A.M., Callado L.F. Neurobiological alterations in alcohol addiction: a review // Adicciones. – 2014. – Vol. 26, No. 4. – P. 360–370. 
5. Kalinina A.G. Toksichnost` alkogolya i alkogol`ny`x napitkov (Alkogolizm. Rukovodstvo dlya vrachej). / pod red. N.N. Ivancza, M.A. Vinnikovoj. – M.: Medicinskoe informacionnoe agentstvo, 2011. – 856 s.
6. Wang G.J., Volkow N.D., Franceschi D., Fowler J.S., Thanos P.K., Scherbaum N., Pappas N., Wong C.T., Hitzemann R.J., Felder C.A. Regional brain metabolism during alcohol intoxication // Alcoholism: Clinical and Experimental Research. – 2000. – Vol. 24, No. 6. – P. 822–829.
7. Chin J.H., Goldstein D.B. Membrane-disordering action of ethanol: variation with membrane cholesterol content and depth of the spin label probe // Molecular Pharmacology. – 1981. – Vol. 19. – P. 425–431.
8. Rottenberg H. Membrane solubility of ethanol in chronic alcoholism. The effect of ethanol feeding and its withdrawal on the protection by alcohol of rat red blood cells from hypotonic hemolysis // Biochimica et Biophysica Acta. – 1986. – Vol. 855, No. 2. – P. 211–222.
9. Harris R.A., Trudell J.R., Mihic S.J. Ethanol’s molecular targets // Science Signaling. – 2008. – Vol. 15, No. 1 (28). – DOI: 10.1126/scisignal.128re7
10. Grobin A.C., Matthews D.B., Devaud L.L., Morrow A.L. The role of GABA(A) receptors in the acute and chronic effects of ethanol // Psychopharmacology (Berl). – 1998. – Vol. 139, No. 1–2. – P. 2–19.
11. Wirkner K., Poelchen W., Köles L., Mühlberg K., Scheibler P., Allgaier C., Illes P. Ethanol-induced inhibition of NMDA receptor channels // Neurochemistry International. – 1999. – Vol. 35, No. 2. – P. 153–162.
12. Diamond I., Gordon A.S. Cellular and molecular neuroscience of alcoholism // Physiological Reviews. – 1997. – Vol. 77, No. 1. – P. 1–20.
13. Weintraub S.J. Diazepam in the treatment of moderate to severe alcohol withdrawal. Review // CNS Drugs. – 2017. – Vol. 31, No. 2. – P. 87–95. – DOI: 10.1007/s40263-016-0403-y
14. Tsai G., Gastfriend D.R., Coyle J.T. The glutamatergic basis of human alcoholism // Am J Psychiatry. – 1995. – Vol. 152, No. 3. – P. 332–340.
15. Tabakoff B, Hoffman PL. The neurobiology of alcohol consumption and alcoholism: an integrative history // Pharmacol Biochem Behav. – 2013. – Vol. 15, No. 113. – P. 20–37. – DOI: 10.1016/j.pbb.2013.10.009
16. Braat S., Kooy R.F. The GABAA Receptor as a Therapeutic Target for Neurodevelopmental Disorders // Neuron. – 2015. – Vol. 3, No. 86 (5). – P. 1119–30. – DOI: 10.1016/j.neuron.2015.03.042
17. Olsen R.W., Liang J. Role of GABAA receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model // Mol Brain. – 2017. – Vol. 20, No. 10 (1). – P. 45. – DOI: 10.1186/s13041-017-0325-8
18. Schuckit M.A. Recognition and management of withdrawal delirium (Delirium Tremens) // N Engl J Med. – 2014. – Vol. 371, No. 22. – P. 2109–13. – DOI: 10.1056/NEJMra1407298
19. Saitz R. Clinical practice. Unhealthy alcohol use // N Engl J Med. – 2005. – Vol. 352. – P. 596–607.
20. Weiss F., Parsons L.H., Schulteis G., Hyytiä P., Lorang M.T., Bloom F.E., Koob G.F. Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats // J Neurosci. – 1996. – Vol. 15, No. 16 (10). – P. 3474–3485.
21. Knutson B., Adams C.M., Fong G.W., Hommer D. Anticipation of increasing monetary reward selectively recruits nucleus accumbens // J Neurosci. – 2001. – Vol. 15, No. 21 (16). – RC159.
22. De Witte P., Pinto E., Ansseau M., Verbanck P. Alcohol and withdrawal: from animal research to clinical issues // Neurosci Biobehav Rev. – 2003. – Vol. 27, No. 3. – P. 189–197.
23. Ivashhenko D.V., Bryun E.A., Savchenko L.M., Sy`chev D.A. Terapiya neoslozhnennogo sindroma otmeny` alkogolya s pozicij dokazatel`noj mediciny`: fokus na benzodiazepiny` // Narkologiya. – 2016. – T. 15, № 12 (180). – S. 83–91.
24. Slawecki C.J., Somes C., Ehlers C.L. Effects of chronic ethanol exposure on neurophysiological responses to corticotropin-releasing factor and neuropeptide Y // Alcohol Alcohol. – 1999. – Vol. 34, No. 3. – P. 289–99.
25. Shabanov P.D., Lebedev A.A. Kortikoliberin, astressin i dejstvie narkogenov // Psixofarmakologiya i biologicheskaya narkologiya. – 2008. – T. 8, № 1–2–2. – S. 2383–2384.
26. Zorrilla E.P., Logrip M.L., Koob G.F. Corticotropin releasing factor: a key role in the neurobiology of addiction // Front Neuroendocrinol. – 2014. – Vol. 35, No. 2. – P. 234–244. – DOI: 10.1016/j.yfrne.2014.01.001
27. Lejoyeux M., Solomon J., Adès J. Benzodiazepine treatment for alcohol-dependent patients // Alcohol Alcohol. – 1998. – Vol. 33. – P. 563–575.
28. Reoux J.P., Saxon A.J., Malte C.A., Baer J.S., Sloan K.L. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial // Alcohol Clin Exp Res. – 2001. – Vol. 25. – P. 1324–1327.
29. Sachdeva A., Choudhary M., Chandra M. Alcohol withdrawal syndrome: benzodiazepines and beyond // J Clin Diagn Res. – 2015. – Vol. 9, No. 9. – P. VE01–VE07. – DOI: 10.7860/JCDR/2015/13407.6538
30. Kaim S, Klett C, Rothfeld B. Treatment of the acute alcohol withdrawal state: a comparison of four drugs // Am J Psychiatry. – 1969. – Vol. 125. – P. 1640–1646.
31. Dean L. Diazepam Therapy and CYP2C19 Genotype. In: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A, editors // Medical Genetics Summaries [Internet]. – Bethesda (MD): National Center for Biotechnology Information (US), 2012.
32. Mandrioli R., Mercolini L., Raggi M.A. Benzodiazepine metabolism: an analytical perspective // Curr Drug Metab. – 2008. – Vol. 9, No. 8. – P. 827–844.
33. Askgaard G., Pottegård A., Fink-Jensen A. Benzodiazepines should still be first-line treatment for alcohol withdrawal // Ugeskr Laeger. – 2017. – Vol. 16, No. 179 (3).
34. Fukasawa T., Suzuki A., Otani K. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines // J Clin Pharm Ther. – 2007. – Vol. 32, No. 4. – P. 333–341.
35. Perry E.C. Inpatient management of acute alcohol withdrawal syndrome // CNS Drugs. – 2014. – Vol. 28, No. 5. – P. 401–10. 
36. Mirijello A., D’Angelo C., Ferrulli A., Vassallo G., Antonelli M., Caputo F., Leggio L., Gasbarrini A., Addolorato G. Identification and management of alcohol withdrawal syndrome // Drugs. – 2015. – Vol. 75, No. 4. – P. 353–365.
37. Lithari C., Klados M.A., Pappas C., Albani M., Kapoukranidou D., Kovatsi L., Bamidis P.D., Papadelis C.L. Alcohol affects the brain’s resting-state network in social drinkers // PLoS One. – 2012. – Vol. 7, No. 10. – DOI: 10.1371/journal.pone.0048641
38. Olsen R.W., DeLorey T.M. GABA Receptor Physiology and Pharmacology // Siegel G.J., Agranoff B.W., Albers R.W. et al. (eds.). Basic Neurochemistry: Molecular, Cellular and Medical Aspects. – 6th edition. –Philadelphia: Lippincott-Raven, 1999. 
39. Vinnikova M.A., Ivanecz N.N. Medikamentozny`e metody` lecheniya narkologicheskix zabolevanij (Narkologiya. Nacional`noe rukovodstvo) / pod red. N.N. Ivancza, I.P. Anoxinoj, M.A. Vinnikovoj. – M.: GE`OTAR-Media, 2016. – 944 s.
40. Afanas`ev V.V. Alkogol`ny`j abstinentny`j sindrom. – SPb.: Intermedika, 2002. – 336 s.
41. Mayo-Smith M.F., Beecher L.H., Fischer T.L., Gorelick D.A., Guillaume J.L., Hill A., Jara G., Kasser C., Melbourne J. Working Group on the Management of Alcohol Withdrawal Delirium, Practice Guidelines Committee, American Society of Addiction Medicine. Management of alcohol withdrawal delirium. An evidence-based practice guideline // Arch Intern Med. – 2004. – Vol. 164, No. 13. – P. 1405–1412.
42. Lady`zhenskij M.Ya., Gorodnichev A.V., Kostyukova E.G. Benzodiazepinovy`e anksiolitiki: vostrebovany` li oni segodnya? / / Sovremennaya terapiya psixicheskix rasstrojstv. – 2014. – № 2. – S. 20–25.
43. Mosolov S.N. Osnovy` psixofarmakoterapii. – M.: Vostok, 1996. – 288 s.
44. Calcaterra N.E., Barrow J.C. Classics in chemical neuroscience: diazepam (valium) // ACS Chem Neurosci. – 2014. – Vol. 16, No. 5 (4). – P. 253–260. – DOI: 10.1021/cn5000056
45. Vorob`eva O.V. Benzodiazepiny`: ot skepticizma k racional`noj pozicii // Medicinskij alfavit. – 2016. – T. 3, № 22 (285). – S. 28–33.
46. World Health Organization Model List of Essential Medicines, 21st List, 2019. – Geneva: World Health Organization, 2019. – Licence: CC BY-NC-SA 3.0 IGO
47. Hollister L.E. Benzodiazepines – an overview // Br J Clin Pharmacol. – 1981. – Vol. 11. – P. 117–119. 
48. Arendt R.M., Greenblatt D.J., Liebisch D.C., Luu M.D., Paul S.M. Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinity // Psychopharmacology (Berl). – 1987. – Vol. 93, No. 1. – P. 72–76. 
49. Greenblatt D.J., Ehrenberg B.L., Gunderman J., Scavone J.M., Tai N.T., Harmatz J.S., Shader R.I. Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam // J Pharmacol Exp Ther. – 1989. – Vol. 250, No. 1. – P. 134–140.
50. Bird RD, Makela EH. Alcohol withdrawal: what is the benzodiazepine of choice? // Ann Pharmacother. – 1994. – Vol. 28, No. 1. – P. 67–71.
51. Sivolap Yu.P. Zloupotreblenie alkogolem i farmakoterapiya alkogolizma // Nevrologiya, nejropsixiatriya, psixosomatika. – 2014. – № 3. – S. 4–9.
52. Holbrook A.M., Crowther R., Lotter A., Cheng C., King D. Diagnosis and management of acute alcohol withdrawal // CMAJ. – 1999. – Vol. 160, No. 5. – P. 675–680.
53. Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal // JAMA. – 1997. – Vol. 9, No. 278 (2). – P. 144–151.
54. Hoffman R.S., Weinhouse G.L. Management of moderate and severe alcohol withdrawal syndromes. – 2019. – URL: https://https://www.uptodate.com/contents/management-of-moderate-and-severe-alcohol-withdrawal-syndromes.
55. Saitz R., Mayo-Smith M.F., Roberts M.S., Redmond H.A., Bernard D.R., Calkins D.R. Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial // JAMA. – 1994. – Vol. 272. – P. 519–23.
56. Daeppen J.B., Gache P., Landry U., Sekera E., Schweizer V., Gloor S., Yersin B. Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial // Arch Intern Med. – 2002. – Vol. 162. – P. 1117–1121.
57. Cassidy E.M., O’Sullivan I., Bradshaw P., Islam T., Onovo C. Symptom-triggered benzodiazepine therapy for alcohol withdrawal syndrome in the emergency department: a comparison with the standard fixed dose benzodiazepine regimen // Emerg Med J. – 2012. – Vol. 29, No. 10. – P. 802–804. – DOI: 10.1136/emermed-2011-200509
58. Holleck J.L., Merchant N., Gunderson C.G. Symptom-Triggered Therapy for Alcohol Withdrawal Syndrome: a Systematic Review and Meta-analysis of Randomized Controlled Trials // J Gen Intern Med. – 2019. – Vol. 34, No. 6. – P. 1018–1024. – DOI: 10.1007/s11606-019-04899-7
59. Sellers E.M., Sandor P., Giles H.G., Khouw V., Greenblatt D.J. Diazepam pharmacokinetics after intravenous administration in alcohol withdrawal // Br J Clin Pharmacol. – 1983. – Vol. 15. – P. 125–127.
60. Manikant S., Tripathi B.M., Chavan B.S. Loading dose diazepam therapy for alcohol withdrawal state // Indian J Med Res. – 1993. – Vol. 98. – P. 170–173.
61. Kattimani S., Bharadwaj B. Clinical management of alcohol withdrawal: A systematic review // Ind Psychiatry J. – 2013. – Vol. 22, No. 2. – P. 100–108. – DOI: 10.4103/0972-6748.132914
62. De Carolis D.D., Rice K.L., Ho L., Willenbring M.L., Cassaro R. Symptom-driven lorazepam protocol for treatment of severe alcohol withdrawal delirium in the intensive care unit // Pharmacotherapy. – 2007. – Vol. 27, No. 4. – P. 510–8.
63. Elholm B., Larsen K., Hornnes N., Zierau F., Becker U. Alcohol withdrawal syndrome: symptom-triggered versus fixed-schedule treatment in an outpatient setting // Alcohol Alcohol. – 2011. – Vol. 46, No. 3. – P. 318–323. – DOI: 10.1093/alcalc/agr020
64. Jaeger T.M., Lohr R.H., Pankratz V.S. Symptom-triggered therapy for alcohol withdrawal syndrome in medical inpatients // Mayo Clin Proc. – 2001. – Vol. 76, No. 7. – P. 695–701.
65. Richman L.S., Garcia C., Bouchard N., Muskin P.R., Dzierba A.L. Evaluation of a Symptom-triggered Protocol for Alcohol Withdrawal for Use in the Emergency Department, General Medical Wards, and Intensive Care Unit // J Psychiatr Pract. – 2019. –Vol. 25, No. 1. – P. 63–70. – DOI: 10.1097/PRA.0000000000000354
66. Sachdeva A., Chandra M., Deshpande S.N. A comparative study of fixed tapering dose regimen versus symptom-triggered regimen of lorazepam for alcohol detoxification // Alcohol Alcohol. – 2014. – Vol. 49, No. 3. – P. 287–291. – DOI: 10.1093/alcalc/agt181
67. Sen S., Grgurich P., Tulolo A., Smith-Freedman A., Lei Y., Gray A., Dargin J. A Symptom-Triggered Benzodiazepine Protocol Utilizing SAS and CIWA-Ar Scoring for the Treatment of Alcohol Withdrawal Syndrome in the Critically Ill // Ann Pharmacother. – 2017. – Vol. 51, No. 2. – P. 101–110. – DOI: 10.1177/1060028016672036
68. Gold J.A., Rimal B., Nolan A., Nelson L.S. A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens // Crit Care Med. – 2007. – Vol. 35, No. 3. – P. 724–730.
69. Hack J.B., Hoffman R.S., Nelson L.S. Resistant alcohol withdrawal: does an unexpectedly large sedative requirement identify these patients early? // J Med Toxicol. – 2006. – Vol. 2, No. 2. – P. 55–60.
70. Wong A., Benedict N.J., Lohr B.R., Pizon A.F., Kane-Gill S.L. Management of benzodiazepine-resistant alcohol withdrawal across a healthcare system: Benzodiazepine dose-escalation with or without propofol // Drug Alcohol Depend. – 2015. – Vol. 1, No. 154. – P. 296-299. – DOI: 10.1016/j.drugalcdep.2015.07.005
71. Benedict N.J., Wong A., Cassidy E., Lohr B.R., Pizon A.F., Smithburger P.L., Falcione B.A., Kirisci L., Kane-Gill S.L. Predictors of resistant alcohol withdrawal (RAW): A retrospective case-control study // Drug Alcohol Depend. – 2018. – Vol. 1, No. 192. – P. 303–308.
72. Ivashhenko D.V., Ivanova E.V., Zastrozhin M.S., Aguzarov A.D., Shipicyn V.V., Savchenko L.M., Bryun E.A., Sy`chev D.A. Bezopasnost` benzodiazepinovy`x trankvilizatorov u pacientov s sindromom zavisimosti ot alkogolya v usloviyax real`noj klinicheskoj praktiki // Klinicheskaya farmakologiya i terapiya. – 2017. – T. 26, № 2. – S. 70–76.
73. Sarff M., Gold J.A. Alcohol withdrawal syndromes in the intensive care unit // Crit Care Med. – 2010. – Vol. 38, No. 9. – P. 494–501.
74. Kang M., Ghassemzadeh S. Toxicity, Benzodiazepine // StatPearls [Internet]. – Treasure Island (FL): StatPearls Publishing, 2018.
75. Korobov N.V. Istoricheskoe znachenie benzodiazepinov i nekotory`e aspekty` ix primeneniya v nastoyashhee vremya // Psixiatriya i psixofarmakoterapiya. – 2015. – T. 17, № 1. – S. 38–43.
76. Sy`chev D.A., Zhuchkov A.V., Tereshhenko O.V., Ivashhenko D.V. Postepennaya otmena (depreskrajbing) benzodiazepinovy`x trankvilizatorov // Nevrologiya, nejropsixiatriya, psixosomatika. – 2019. – T. 11, № 1. – S. 89–95.
77. Mosolov S.N. Trevozhny`e i depressivny`e rasstrojstva: komorbidnost` i terapiya. – M.: Artinfo Pablishing, 2007. – 63 s.
78. Mendelevich V.D. Problema addiktofobii v sovremennoj psixiatrii (benzodiazepiny` i drugie psixofarmakologicheskie sredstva) // Zhurnal nevrologii i psixiatrii imeni C.C. Korsakova. – 2019. – T. 119, № 1–2. – S. 75–81.
79. Sivolap Yu.P. Tixaya addikciya: zloupotreblenie snotvorny`mi sredstvami // E`ffektivnaya farmakoterapiya. – 2014. – № 22. – S. 30–34.
80. Konopka A., Mak M., Grzywacz A., Murawiec S., Samochowiec J. Genetic and psychosocial factors for benzodiazepine addiction. An analysis based on the results of the authors’ own research conducted in a group of benzodiazepine addicted and non-addicted individuals // Postepy Hig Med Dosw (online). – 2017. – Vol. 71. – P. 205–213. – DOI: 10.5604/01.3001.0010.3805
81. Hallfors D.D., Saxe L. The dependence potential of short half-life benzodiazepines: a meta-analysis // American Journal of Public Health. – 1993. – Vol. 83, No. 9. – P. 1300–1304. – DOI: 10.2105/ajph.83.9.1300